报价延迟最少15分钟:2025/08/26 05:54 EDT
盘前时段
|
||||
|
115.08 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
114.97
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.99/2.22
|
|
企业价值
4.60B
|
| 资产负债 |
|
每股账面净值
9.33
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
23.60M
|
|
每股收益
5.63
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/08/26 05:54 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
